SEC Form 4Coverage since Aug 15, 2025Open-market trades only
$PTCT insider trading
Over the last 12 months, PTC Therapeutics insiders reported no purchases and 70 sales totaling $63.2M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $63.2M 70 events
- Events · 12m
- 70 Form 4 filings, grouped
- Insiders · 12m
- 13 distinct reporters
- 10b5-1 share
- 100% of events, not dollars
Side
Price · $PTCT · 3Mvia TradingView
Top insiders · 12m
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER16× · $26.0M
Boulding Mark ElliottEXEC. VP AND CLO12× · $5.5M
Klein Matthew B.CHIEF EXECUTIVE OFFICER8× · $3.3M
Reeve Emma—6× · $4.2M
Pauwels EricCHIEF BUSINESS OFFICER6× · $7.5M
All insider trades
50 of 76 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | SCHMERTZLER MICHAELD | ▼ Sale | 20,000 | $67.49 | $1.3M | -1.5% | plan · 4 tranches · indirect |
| Sep 10, 2026 | SCHMERTZLER MICHAELD | ▼ Sale | 20,000 | $67.59 | $1.4M | -1.5% | plan · 3 tranches · indirect |
| Aug 27, 2026 | SCHMERTZLER MICHAELD | ▼ Sale | 25,000 | $72.26 | $1.8M | -1.8% | plan · 4 tranches · indirect |
| Aug 20, 2026 | SCHMERTZLER MICHAELD | ▼ Sale | 25,000 | $72.22 | $1.8M | -1.8% | plan · 5 tranches · indirect |
| Aug 17, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 2,813 | $72.57 | $204K | -2.6% | plan · 2 tranches |
| Aug 4, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 10,292 | $68.57 | $706K | -2.6% | plan |
| Jul 14, 2026 | Gravier PierreCHIEF FINANCIAL OFFICER · O | ▼ Sale | 3,494 | $80.35 | $281K | -4% | plan |
| Jul 9, 2026 | Smith Mary L.D | ▼ Sale | 15,834 | $90 | $1.4M | -42.1% | plan · 2 tranches |
| Jul 9, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 2,464 | $90.25 | $222K | -3.9% | plan |
| Jul 7, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 46,774 | $87.52 | $4.1M | -43.7% | plan · 8 tranches |
| Jul 6, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 5,079 | $85.08 | $432K | -4.6% | plan · 8 tranches |
| Jun 26, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 8,130 | $85.26 | $693K | -11.9% | plan · 2 tranches |
| Jun 25, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 26,283 | $85.78 | $2.3M | -30.4% | plan · 7 tranches |
| Jun 22, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 23,749 | $80.9 | $1.9M | -28.3% | plan · 2 tranches |
| Jun 17, 2026 | Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 19,686 | $75.56 | $1.5M | -21.9% | plan |
| Jun 17, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 10,462 | $78.65 | $823K | -9% | plan · 4 tranches |
| Jun 10, 2026 | Pauwels EricCHIEF BUSINESS OFFICER · O | ▼ Sale | 21,277 | $75 | $1.6M | -22.5% | plan · 2 tranches |
| Apr 21, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 2,850 | $70.91 | $202K | -0.7% | plan |
| Apr 6, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 2,265 | $69.45 | $157K | -2.1% | plan · 2 tranches |
| Apr 2, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · O | ▼ Sale | 829 | $67.99 | $56K | -1% | plan |
| Apr 1, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 52,003 | $69.04 | $3.6M | -46.4% | plan · 3 tranches |
| Mar 12, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 2,662 | $64.08 | $171K | -0.7% | plan |
| Mar 10, 2026 | Okey StephanieD | ▼ Sale | 15,167 | $70 | $1.1M | -65.5% | plan · 2 tranches |
| Mar 5, 2026 | Okey StephanieD | ▼ Sale | 6,333 | $63.38 | $401K | -44.2% | plan |
| Mar 5, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · O | ▼ Sale | 10,000 | $63.38 | $634K | -11.1% | plan |
| Mar 5, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 3,989 | $63.38 | $253K | -59.3% | plan · indirect |
| Feb 19, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 3,019 | $69.48 | $210K | -2.8% | plan · 4 tranches |
| Feb 18, 2026 | Gravier PierreCHIEF FINANCIAL OFFICER · O | ▼ Sale | 2,992 | $69.36 | $208K | -3.3% | plan |
| Feb 18, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 7,371 | $69.36 | $511K | -1.9% | plan |
| Feb 18, 2026 | Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 2,494 | $69.36 | $173K | -3.4% | plan |
| Feb 18, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · O | ▼ Sale | 2,484 | $69.36 | $172K | -2.7% | plan |
| Feb 18, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 65 | $69.36 | $5K | -1% | plan · indirect |
| Feb 18, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 3,056 | $69.36 | $212K | -2.7% | plan |
| Feb 18, 2026 | Pauwels EricCHIEF BUSINESS OFFICER · O | ▼ Sale | 3,019 | $69.36 | $209K | -3.8% | plan |
| Feb 18, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 5,894 | $69.33 | $409K | -5.2% | plan · 3 tranches |
| Jan 12, 2026 | Pauwels EricCHIEF BUSINESS OFFICER · O | ▼ Sale | 7,348 | $77.02 | $566K | -8.4% | plan · 5 tranches |
| Jan 9, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 6,347 | $77.06 | $489K | -5.4% | plan · 6 tranches |
| Jan 8, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 2,514 | $76.45 | $192K | -0.6% | plan |
| Jan 8, 2026 | Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 1,034 | $76.45 | $79K | -1.4% | plan |
| Jan 8, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · O | ▼ Sale | 866 | $76.45 | $66K | -0.9% | plan |
| Jan 8, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 59 | $76.45 | $5K | -0.9% | plan · indirect |
| Jan 8, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 881 | $76.45 | $67K | -0.8% | plan |
| Jan 7, 2026 | Klein Matthew B.CHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 8,165 | $77.15 | $630K | -2% | plan · 2 tranches |
| Jan 7, 2026 | Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER · O | ▼ Sale | 2,616 | $77.19 | $202K | -3.4% | plan · 2 tranches |
| Jan 7, 2026 | Golden Lee ScottEVP & CHIEF MEDICAL OFFICER · O | ▼ Sale | 1,982 | $77.12 | $153K | -2.1% | plan · 2 tranches |
| Jan 7, 2026 | Boulding Mark ElliottEXEC. VP AND CLO · O | ▼ Sale | 6,618 | $77.31 | $512K | -5.3% | plan · 8 tranches |
| Jan 7, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 106 | $77.21 | $8K | -1.5% | plan · 2 tranches · indirect |
| Jan 7, 2026 | Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER · O | ▼ Sale | 2,305 | $77.19 | $178K | -1.9% | plan · 2 tranches |
| Jan 7, 2026 | Pauwels EricCHIEF BUSINESS OFFICER · O | ▼ Sale | 3,141 | $77.18 | $242K | -3.5% | plan · 2 tranches |
| Jan 6, 2026 | Gravier PierreCHIEF FINANCIAL OFFICER · O | ▼ Sale | 2,139 | $76.95 | $165K | -2.3% | plan |
Every $PTCT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? PTC Therapeutics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PTCT feed.